Details for New Drug Application (NDA): 084517
✉ Email this page to a colleague
NDA 084517 describes PROMAZINE HYDROCHLORIDE, which is a drug marketed by Watson Labs and is included in two NDAs. Additional details are available on the PROMAZINE HYDROCHLORIDE profile page.
The generic ingredient in PROMAZINE HYDROCHLORIDE is promazine hydrochloride. There are thirty-seven drug master file entries for this compound. Additional details are available on the promazine hydrochloride profile page.
The generic ingredient in PROMAZINE HYDROCHLORIDE is promazine hydrochloride. There are thirty-seven drug master file entries for this compound. Additional details are available on the promazine hydrochloride profile page.
Summary for 084517
| Tradename: | PROMAZINE HYDROCHLORIDE |
| Applicant: | Watson Labs |
| Ingredient: | promazine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 084517
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 50MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
